Article

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

2022-11-15

Abstract excerpt

Background: AML is characterized by a differentiation block leading to the accumulation of immature cells. Therefore therapies capable of inducing differentiation of these immature cells, particularly if also associated with antiproliferative activity, are considered an attractive therapeutic approach in acute leukemias. Histone-lysine N-methyltransferase-2A (KMT2A; also known as Mixed lineage leukemia 1 (MLL1))-f...

Topics

Open a Topic to create a Post that cites this publication.

Acute Myeloid Leukemia Research

Identifiers and source

Literature Corpus work: 501fe16b-2654-58fb-b61e-f7d1339cfc9f
DOI: 10.1182/blood-2022-168921

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute LeukemiaDOI 10.1182/blood-2022-168921Read

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemiasSemantic proximity Read

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read

Therapeutic Targeting of the Menin–KMT2A InteractionSemantic proximity Read

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemiaSemantic proximity Read

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.Semantic proximity Read

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read